Lung Cancer Clinical Trial
Official title:
Pilot Neoadjuvant Study of ZD1839 (IRESSA®) as Single Agent Preoperative Therapy for Clinical Stage 1A and 1B (T1-2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC) With Molecular Correlates
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving gefitinib before surgery may shrink the tumor so it can be
removed.
PURPOSE: This phase II trial is studying how well gefitinib works in treating patients who
are undergoing surgery for stage I, stage II, or stage III non-small cell lung cancer.
Status | Terminated |
Enrollment | 42 |
Est. completion date | March 2009 |
Est. primary completion date | May 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed resectable non-small cell lung cancer (NSCLC), meeting 1 of the following clinical staging criteria: - Stage IA or IB (T1-2, N0) - Stage II (T1-2, N1 with negative mediastinoscopy or T3, N0) - Stage IIIA (T3, N1 with negative mediastinoscopy) - Level 10 hilar nodes may be positive provided mediastinoscopy is negative - The following are not allowed (as evidenced by clinical staging criteria [CT scan, positron-emission tomography (PET) scan, or mediastinoscopy): - Positive N2 lymph nodes (ipsilateral/subcarinal mediastinal lymph nodes) - Positive N3 lymph nodes (contralateral mediastinal/hilar and supraclavicular/scalene lymph nodes) - T4 primary tumor (malignant pleural effusion or mediastinal invasion) - Symptomatic tumors (T3, N0-1) involving the superior sulcus (i.e., Pancoast tumors) - Measurable disease by contrast-enhanced CT scan - No metastatic disease (except peribronchial or hilar lymph node involvement [N1]) by fludeoxyglucose F 18 PET scan - No malignant pleural effusion by preoperative evaluation - Pleural effusions visible only on CT scan that are not large enough for safe thoracentesis are allowed - No exudative effusions (even if cytologically negative), as evidenced by any of the following: - Ratio of pleural fluid protein to serum protein > 0.5 - Ratio of pleural fluid lactic dehydrogenase (LDH) to serum LDH = 0.6 - Pleural fluid LDH > 200 IU/L - No superior vena cava syndrome - No spinal cord compression PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Eastern Cooperative Oncology Group (ECOG) 0-1 Life expectancy - Not specified Hematopoietic - WBC = 4,000/mm^3 - Absolute granulocyte count = 1,500/mm^3 - Platelet count = 100,000/mm^3 Hepatic - Bilirubin = 1.5 times upper limit of normal (ULN) - AST or ALT = 2 times ULN - Alkaline phosphatase = 2 times ULN Renal - Creatinine < 1.5 times ULN Cardiovascular - No uncontrolled ventricular arrhythmia - No myocardial infarction within the past 3 months Pulmonary - Pre-resection FEV_1 > 2.0 L OR - Predicted post-resection FEV_1 > 1.0 L - No clinically active interstitial lung disease - Chronic stable asymptomatic radiographic changes allowed - No post-obstructive pneumonia Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Willing to provide tumor biopsy pre- and post-gefitinib administration AND undergo PET scan - No known severe hypersensitivity to study drug or any of its excipients - No uncontrolled major seizure disorder - No unstable or uncontrolled diabetes mellitus - No serious infection requiring IV antibiotics - No grade 3 neuropathy - No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix - No other unstable or serious medical condition that would preclude study treatment or surgery - No psychiatric disorder that would preclude giving informed consent - No psychological, familial, sociological, or geographical condition that would preclude study compliance and follow up - No other significant clinical disorder or laboratory finding that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior or concurrent systemic chemotherapy for NSCLC Endocrine therapy - Not specified Radiotherapy - No prior or concurrent radiotherapy for NSCLC Surgery - Recovered from prior oncologic or other major surgery - At least 5 years since prior resection of lung disease - No prior surgery for NSCLC - No concurrent ophthalmic surgery Other - More than 30 days since prior non-approved or investigational drugs - No other concurrent therapy for NSCLC - No other concurrent investigational therapy - No concurrent use of any of the following medications: - Phenytoin - Carbamazepine - Barbiturates (e.g., phenobarbital) - Rifampin - Hypericum perforatum (St. John's wort) |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
H. Lee Moffitt Cancer Center and Research Institute | AstraZeneca, National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Response Rate (ORR) | Objective Response Rate according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Investigators planned to use this pilot study of neoadjuvant ZD1839 in patients with resectable NSCLC to specifically correlate molecular parameters to the primary clinical study endpoint clinical response assessed by CT response and PET scan response of the primary tumor. | 3 years | No |
Secondary | Frequency of Toxicity Related to Study Treatment | Review of adverse events utilizing Common Toxicity Criteria (CTC) V3. To estimate the safety, tolerability, and feasibility of preoperative ZD1839 in patients with resectable Stage IA/IB, II and selected IIIA NSCLC by evaluating toxicity and operability after preoperative ZD1839. | 3 years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|